Anti-TB dose ‘BPaL’ gets global approval

Share with Your Friends

Anti-TB dose ‘BPaL’ gets global approval

Small anti-tuberculosis dose Anti-TB dose ‘BPaL’ has received global approval if a recent test is ‘positive’.

A short-term treatment of six months called BPaL has shown favorable results in patients with tuberculosis (TB).

क्षय रोग-रोधी खुराक 'BPaL' को वैश्विक मंजूरी मिली

BPaL is a 6-monthly dosed treatment. It is an oral drug and is a three-drug dosage.

It is used to treat patients suffering from highly drug-resistant forms of tuberculosis.

BPaL is a combination of three new antibiotics. These three medicines are: bedaquiline, pretomanid, and linezolid.

TB Alliance’s BPaL drug has reduced the treatment time of tuberculosis from 18 months to 6 months. Also, the reported success rate is 90%. This rate can prove to be important in the eradication of tuberculosis. (The TB Alliance is a non-profit organization.)

Drug-resistant tuberculosis occurs when bacteria develop resistance to the drugs used to treat tuberculosis.

Types of drug resistant tuberculosis

  • Mono-resistance: Resistance to first-line anti-tuberculosis drugs only.
  • Poly-resistance: Resistance to more than one first-line anti-tuberculosis drug excluding isoniazid and rifampicin drugs.
  • Multi-drug resistance (MDR): Develops resistance to at least both isoniazid and rifampicin.
  • Extended drug resistance (XDR): Resistance against any fluoroquinolone other than MDR, as well as resistance against at least one of the three second-line injectable drugs (capreomycin, kanamycin and amikacin).
  • Rifampicin resistance (RR): Resistance to rifampicin drug in the form of single-resistance, multiple-resistance, MDR or XDR.

Tuberculosis (TB)

  • Tuberculosis is caused by a bacterium called Mycobacterium tuberculosis, which most often affects the lungs. It can also affect other organs.
  • Most common drugs used to treat tuberculosis include isoniazid, rifampin, ethambutol, pyrazinamide, etc.
  • BCG is currently the only licensed vaccine available for the prevention of tuberculosis.

Source- The Hindu

Download Our App

More Current Affairs

Click to Join Our Current Affairs WhatsApp Group

Join Our Whatsapp Group For Daily, Weekly, Monthly Current Affairs Compilation & Daily Mains Answer Writing Test & Current Affairs MCQ

In Our Current Affairs WhatsApp Group you will get daily Mains Answer Writing Question PDF and Word File, Daily Current Affairs PDF and So Much More in Free So Join Now

Register For Latest Notification

Register Yourself For Latest Current Affairs

December 2022
« Nov    

Mains Answer Writing Practice

Recent Current Affairs (English)

Current Affairs (हिन्दी)

Subscribe Our Youtube Channel

Register now

Get Free Counselling Session with mentor

Download App

Get Youth Pathshala App For Free

Open chat
Youth Destination IAS . PCS
To get access
- NCERT Classes
- Current Affairs Magazine
- IAS Booklet
- Complete syllabus analysis
- Demo classes